Cargando…

559. Efficacy and Tolerability of Integrase Inhibitors: Experiences From a Nationwide Real-Life Cohort

BACKGROUND: The integrase strand transfer inhibitors (INSTIs) are widely used in first-line and alternative antiretroviral therapy. Observational studies have documented a 2–12% incidence of adverse drug reactions sometimes leading to INSTI discontinuation. METHODS: Prospectively collected cohort da...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lakatos, Botond, Lonkai, Bernadett, Szlávik, János
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2018
Materias:	Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6255420/ http://dx.doi.org/10.1093/ofid/ofy210.567

Ejemplares similares

559. A Nationwide Survey of COVID-19 Management in the Dominican Republic Over the Course of the Pandemic
por: Mena Lora, Alfredo J, et al.
Publicado: (2021)

Invasive fungal infections among critically ill adult COVID-19 patients: First experiences from the national centre in Hungary
por: Szabo, Balint Gergely, et al.
Publicado: (2021)

PT559. The Effect of Escitalopram on Mood and Cognition in Depressive Alzheimer’s Disease Subjects
por: An, Hoyoung, et al.
Publicado: (2016)

Use of convalescent plasma therapy in hospitalised adult patients with non-critical COVID-19: a focus on the elderly from Hungary
por: Kiss-Dala, Noemi, et al.
Publicado: (2022)

2060. Evaluation of the real world incidence of integrase inhibitor resistance since adoption as guideline preferred therapy
por: Januszka, Jenna, et al.
Publicado: (2022)

Favipiravir treatment does not influence disease progression among adult patients hospitalized with moderate-to-severe COVID-19: a prospective, sequential cohort study from Hungary
por: Szabo, Balint Gergely, et al.
Publicado: (2021)

Outcomes of high-risk adult outpatients treated with early remdesivir therapy during the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) omicron era: experiences from the national centre of Hungary
por: Gáspár, Zsófia, et al.
Publicado: (2023)

559. Results of the implementation of a molecular pneumonia panel at a hospital in the Dominican Republic: expanding the scope of detection and management
por: Guzman-Marte, Anel E, et al.
Publicado: (2023)

559. Outcomes of Convalescent Plasma Transfusion for SARS-CoV2 Patients in the Intensive Care Unit
por: Khalid, Rabeeya, et al.
Publicado: (2020)

559. Two Different Beasts: Comparing Epidemiology of Healthcare-Associated vs. Community-Acquired Methicillin-Resistant Staphylococcus aureus Bacteremia
por: McLaughlin, Luke, et al.
Publicado: (2019)

Weight Gain After Switch from Efavirenz-Based to Integrase Inhibitor-Based Regimens
por: Norwood, Jamison, et al.
Publicado: (2017)

556. Factors Associated with Integrase Strand Transfer Inhibitor Use Between 2008 and 2015
por: O’Halloran, Jane, et al.
Publicado: (2018)

559 Risk Factors for Bronchial Asthma in Central Havana in the Period 1995–2010
por: Guerrero, Adelquis, et al.
Publicado: (2012)

889. Early Discontinuations and Adverse Events Among Treatment-Naïve Patients Initiating Integrase Inhibitors in a Real-world Setting
por: Rolle, Charlotte-Paige M, et al.
Publicado: (2021)

538. Integrase Inhibitor-Based HAART Is Associated with Greater BMI Gains in Blacks, Hispanics, and Women
por: Bedimo, Roger, et al.
Publicado: (2018)

Resistance to Integrase Inhibitors
por: Métifiot, Mathieu, et al.
Publicado: (2010)

Characterization of natural polymorphic sites of the HIV-1 integrase before the introduction of HIV-1 integrase inhibitors in Germany
por: Meixenberger, Karolin, et al.
Publicado: (2014)

Novel 3′-Processing Integrase Activity Assay by Real-Time PCR for Screening and Identification of HIV-1 Integrase Inhibitors
por: Sakkhachornphop, Supachai, et al.
Publicado: (2015)

Integrase inhibitors effective against human T-cell leukemia virus type 1
por: Seegulam, Muhammad E, et al.
Publicado: (2011)

Treatment with Raltegravir, a retroviral integrase inhibitor, in patients infected with HTLV-1
por: Treviño, Ana, et al.
Publicado: (2011)

946. Risk factors and Metabolic Implications of Integrase Inhibitor Associated Weight Gain
por: Asundi, Archana, et al.
Publicado: (2020)

Virologic and immunologic outcomes of treatment with integrase inhibitors in a real-world setting: The RESPOND cohort consortium
por: Neesgaard, Bastian, et al.
Publicado: (2020)

Baricitinib vs tocilizumab treatment for hospitalized adult patients with severe COVID-19 and associated cytokine storm: a prospective, investigational, real-world study
por: Lakatos, Botond, et al.
Publicado: (2022)

334. Weight Change Associated with Antiretroviral Therapy Switch to Integrase Strand Transfer Inhibitor-Based Regimens
por: Saber, Saghar, et al.
Publicado: (2019)

1987. "Association Between Integrase Inhibitor Plasma Concentrations and Body Weight Gain in Women Living with HIV"
por: Lahiri, Cecile D, et al.
Publicado: (2023)

903. A Real-world Study Assessing the Risk of Lipid Changes and Other Metabolic Effects Associated with Integrase Inhibitor-based Antiretroviral Therapy
por: Gruss, Zachary, et al.
Publicado: (2021)

345. Acute Onset Diabetic Ketoacidosis/Hyperosmolar Hyperglycemic State in Patients Taking Integrase Strand Transfer Inhibitors
por: Ntem-Mensah, Afua Duker, et al.
Publicado: (2019)

1518. Prevalence of Integrase Inhibitor Resistance within an Urban Clinic Network After Adoption as First-line Therapy
por: Januszka, Jenna E, et al.
Publicado: (2023)

Comprehensive analysis on 559 cases of adrenal incidentalomas in the elderly Chinese
por: Li, Tuo, et al.
Publicado: (2018)

FRI559 An Uncommon Association Of Two Common Etiologies Of Hyperthyroidism
por: Kian Chew, Chee
Publicado: (2023)

Extracorporeal Photopheresis as a Possible Therapeutic Approach for Adults with Severe and Critical COVID-19 Non-Responsive to Standard Treatment: A Pilot Investigational Study
por: Szabó, Bálint Gergely, et al.
Publicado: (2023)

1566. Determinants associated with weight gain among persons with HIV who switch to integrase strand transfer inhibitors (INSTI)
por: Cutshaw, Melissa Klein, et al.
Publicado: (2023)

Relationship between HIV integrase polymorphisms and integrase inhibitor susceptibility: An in silico analysis
por: Hutapea, Hotma Martogi Lorensi, et al.
Publicado: (2018)

Variability in HIV-1 Integrase Gene and 3′-Polypurine Tract Sequences in Cameroon Clinical Isolates, and Implications for Integrase Inhibitors Efficacy
por: Acharya, Arpan, et al.
Publicado: (2020)

1985. A Prospective, Randomized Trial to Assess a Protease Inhibitor–based Regimen Switch Strategy to Manage Integrase Inhibitor–related Weight Gain
por: Short, William R, et al.
Publicado: (2023)

Integrase Inhibitor Prescribing Disparities in the DC and Johns Hopkins HIV Cohorts
por: Monroe, Anne K, et al.
Publicado: (2021)

HIV-2 Integrase Variation in Integrase Inhibitor-Naïve Adults in Senegal, West Africa
por: Gottlieb, Geoffrey S., et al.
Publicado: (2011)

HIV-1 integrase tetramers are the antiviral target of pyridine-based allosteric integrase inhibitors
por: Koneru, Pratibha C, et al.
Publicado: (2019)

High resolution spectral atlas of nitrogen dioxide 559–597 nm
por: Uehara, Kiyoji, et al.
Publicado: (1985)

332. Exploring the Prevalence and Characteristics of Weight Gain and other Metabolic Changes in Patients with HIV Infection Switching to Integrase Inhibitor Containing ART
por: Zimmerman, Matty, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_nusmumkp2gfklq4a8q2lt29tpn